Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chitosan nanoparticles as antigen vehicles to induce effective tumor specific T cell responses.

PloS one - 1 Jan 2020

Walter Frederik, Winter Elsa, Rahn Sascha, Heidland Judith, Meier Saskia, Struzek Anna-Maria, Lettau Marcus, Philipp Lisa-Marie, Beckinger Silje, Otto Lilli, Möller Julia Luisa, Helm Ole, Wesch Daniela, Scherließ Regina, Sebens Susanne

Abstract excerpt

Cancer vaccinations sensitize the immune system to recognize tumor-specific antigens de novo or boosting preexisting immune responses. Dendritic cells (DCs) are regarded as the most potent antigen presenting cells (APCs) for induction of (cancer) antigen-specific CD8+ T cell responses. Chitosan nanoparticles (CNPs) used as delivery vehicle have been shown to improve anti-tumor responses. This study aimed at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chitosan

Share to Coculture Techniques

Share to Dendritic Cells

Share to Drug Carriers

Share to Nanoparticles

Share to Vaccination

Source

Open in PubMed Open full text

Identifiers

PMID: 32997691
DOI: 10.1371/journal.pone.0239369
PMCID: PMC7526875

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chitosan nanoparticles as antigen vehicles to induce effective tumor specific T cell responses.PMID 32997691Read ↗

Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy.Semantic proximity Read ↗

Strategies for developing and optimizing cancer vaccinesSemantic proximity Read ↗

Optimized mobilization of MHC class I- and II- restricted immunity by dendritic cell vaccine potentiates cancer therapySemantic proximity Read ↗

Targeted delivery of vaccine to dendritic cells by chitosan nanoparticles conjugated with a targeting peptide ligand selected by phage display technique.Semantic proximity Read ↗

Lipid-polymer hybrid nanoparticles utilize B cells and dendritic cells to elicit distinct antigen-specific CD4 <sup>+</sup> and CD8 <sup>+</sup> T cell responsesSemantic proximity Read ↗

Targeting human dendritic cells in situ to improve vaccines.Semantic proximity Read ↗

Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine.Semantic proximity Read ↗

Second generation of LNP based mRNA vaccine leads to a T cell–inflamed tumor microenvironment favorable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumor modelSemantic proximity Read ↗

Neoantigen enriched biomimetic nanovaccine for personalized cancer immunotherapySemantic proximity Read ↗

Pro-inflammatory chitosan/poly(γ-glutamic acid) nanoparticles modulate human antigen-presenting cells phenotype and revert their pro-invasive capacity.Semantic proximity Read ↗

Efficient Nanovaccine Delivery in Cancer ImmunotherapySemantic proximity Read ↗

Spleen-targeted NeoPol-mL242 mRNA vaccine induces robust T-cell responses in a hepatocellular carcinoma modelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.